SELLAS Life Sciences Group, Inc. (SLS)

US — Healthcare Sector

Peers: NLSP MREO ARAV DAWN RVPHW EYEN CGTX RNAZ KOD OCUP RVPH PLX EYPT ZURA ENVB EFTR IMMX ELEV ANVS SAVA AXSM MCRB

Automate Your Wheel Strategy on SLS

With Tiblio's Option Bot, you can configure your own wheel strategy including SLS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol SLS
Rev/Share 0.0
Book/Share 0.3163
PB 5.4062
Debt/Equity 0.0313
CurrentRatio 4.6418
ROIC -1.3225

MktCap 170619525.0
FreeCF/Share -0.3841
PFCF -5.0612
PE -5.5319
Debt/Assets 0.0249
DivYield 0
ROE -1.9367

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 2
P/B Score 2
D/E Score 3

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

SLS
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML Cells New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML Cells

image for news SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

SLS
Published: March 31, 2025 by: Seeking Alpha
Sentiment: Neutral

Sellas Life Sciences Group, Inc.'s stock has dropped significantly, with a Hold rating due to uncertainty around the final Phase 3 trial data for GPS in AML. Interim results for GPS are promising but inconclusive; the trial continues until 80 patients die, creating investment uncertainty and ongoing cash burn. The company raised $25M in January 2025, extending its runway to late 2025, but may need more funds for regulatory and commercial plans.

image for news Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

SLS
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

- Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients -

image for news SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

About SELLAS Life Sciences Group, Inc. (SLS)

IPO Date 2008-03-12
Website https://www.sellaslifesciences.com
Industry Biotechnology
CEO Dr. Angelos M. Stergiou M.D., ScD h.c.
Employees 15

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.